An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 213378
Company: ALKERMES INC

Medication Guide

Products on NDA 213378

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
LYBALVI	OLANZAPINE; SAMIDORPHAN L-MALATE	5MG;EQ 10MG BASE	TABLET;ORAL	Prescription	None	Yes	Yes
LYBALVI	OLANZAPINE; SAMIDORPHAN L-MALATE	10MG;EQ 10MG BASE	TABLET;ORAL	Prescription	None	Yes	No
LYBALVI	OLANZAPINE; SAMIDORPHAN L-MALATE	15MG;EQ 10MG BASE	TABLET;ORAL	Prescription	None	Yes	No
LYBALVI	OLANZAPINE; SAMIDORPHAN L-MALATE	20MG;EQ 10MG BASE	TABLET;ORAL	Prescription	None	Yes	No

Approval Date(s) and History, Letters, Labels, Reviews for NDA 213378

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
05/28/2021	ORIG-2	Approval	Type 1 - New Molecular Entity and Type 4 - New Combination	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/213378Orig1s000, Orig2s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000TOC.cfm
05/28/2021	ORIG-1	Approval	Type 1 - New Molecular Entity and Type 4 - New Combination	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/213378Orig1s000, Orig2s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000TOC.cfm

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
01/30/2024	SUPPL-7	Labeling-Package Insert, Labeling-Medication Guide	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213378s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213378Orig1s007ltr.pdf
09/25/2023	SUPPL-5	Labeling-Medication Guide, Labeling-Container/Carton Labels, Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213378Orig1s005lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/213378Orig1s005ltr.pdf

Labels for NDA 213378

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
01/30/2024	SUPPL-7	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213378s007lbl.pdf
01/30/2024	SUPPL-7	Labeling-Medication Guide	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213378s007lbl.pdf
09/25/2023	SUPPL-5	Labeling-Medication Guide	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213378Orig1s005lbl.pdf
09/25/2023	SUPPL-5	Labeling-Container/Carton Labels	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213378Orig1s005lbl.pdf
09/25/2023	SUPPL-5	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213378Orig1s005lbl.pdf
05/28/2021	ORIG-2	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf
05/28/2021	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf

Top